ES2572952T3
(es)
|
2005-11-07 |
2016-06-03 |
Indiana University Research And Technology Corporation |
Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
|
ES2628063T3
(es)
|
2007-01-05 |
2017-08-01 |
Indiana University Research And Technology Corporation |
Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
|
KR20090119876A
(ko)
|
2007-02-15 |
2009-11-20 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루카곤/glp-1 수용체 공동-항진물질
|
WO2009058662A2
(fr)
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Antagonistes du glucagon
|
ES2558155T3
(es)
|
2007-10-30 |
2016-02-02 |
Indiana University Research And Technology Corporation |
Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
|
JP2011511778A
(ja)
|
2008-01-30 |
2011-04-14 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
エステルに基づいたペプチドプロドラッグ
|
MX2010008024A
(es)
*
|
2008-02-01 |
2010-12-21 |
Ascendis Pharma As |
Profarmaco que comprende un enlazador que se puede separar por si mismo.
|
PT3050576T
(pt)
|
2008-04-29 |
2021-06-01 |
Ascendis Pharma Growth Disorders Div A/S |
Compostos recombinantes e peguilados da hormona de crescimento humana
|
KR20110040760A
(ko)
|
2008-06-17 |
2011-04-20 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
대사 질환 및 비만 치료용 gip-기초된 혼합형 항진제
|
CN103641907A
(zh)
|
2008-06-17 |
2014-03-19 |
印第安纳大学研究及科技有限公司 |
胰高血糖素/glp-1受体共激动剂
|
CN104447980A
(zh)
|
2008-06-17 |
2015-03-25 |
印第安纳大学研究及科技有限公司 |
在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
|
WO2010042596A2
(fr)
*
|
2008-10-08 |
2010-04-15 |
The Uab Research Foundation |
Groupes protecteurs photo-activés
|
EP2376520B1
(fr)
|
2008-12-19 |
2014-02-12 |
Indiana University Research&Technology Corporation |
Analogues d'insuline
|
EP2376097A4
(fr)
|
2008-12-19 |
2012-10-03 |
Univ Indiana Res & Tech Corp |
Promédicaments peptidiques de la superfamille du glucagon à base d'amide
|
EP2376521B1
(fr)
|
2008-12-19 |
2016-04-13 |
Indiana University Research and Technology Corporation |
Promédicaments insuliniques à base d'amide
|
WO2010099200A1
(fr)
|
2009-02-24 |
2010-09-02 |
Nektar Therapeutics |
Conjugués oligomère-acides aminés
|
PE20120792A1
(es)
|
2009-05-20 |
2012-07-27 |
Biomarin Pharm Inc |
Variantes de peptidos natriureticos de tipo c
|
MX2011013625A
(es)
|
2009-06-16 |
2012-01-20 |
Univ Indiana Res & Tech Corp |
Compuestos glucagon activo de receptor de gip.
|
KR20120089843A
(ko)
*
|
2009-07-31 |
2012-08-14 |
사노피-아벤티스 도이칠란트 게엠베하 |
인슐린 링커 접합체를 포함한 프로드럭
|
EP2459227B1
(fr)
*
|
2009-07-31 |
2021-03-17 |
Ascendis Pharma A/S |
Promédicaments contenant une amine aromatique liée à un support par liaison amide
|
WO2011012715A1
(fr)
|
2009-07-31 |
2011-02-03 |
Ascendis Pharma As |
Hydrogels insolubles dans leau à base de polyéthylène glycol biodégradable
|
DK2459171T3
(en)
|
2009-07-31 |
2017-09-25 |
Sanofi Aventis Deutschland |
Long-acting insulin composition
|
EP2485712A1
(fr)
|
2009-10-06 |
2012-08-15 |
Ascendis Pharma A/S |
Composition sous-cutanée de palipéridone
|
CA2776723C
(fr)
|
2009-10-29 |
2018-09-25 |
Ascendis Pharma As |
Sterilisation d'hydrogels biodegradables
|
DK2512450T3
(en)
*
|
2009-12-15 |
2018-04-23 |
Ascendis Pharma Endocrinology Div A/S |
Dry growth hormone composition transiently bound to a polymer carrier
|
US8703701B2
(en)
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
US9561285B2
(en)
|
2010-01-22 |
2017-02-07 |
Ascendis Pharma As |
Carrier-linked carbamate prodrug linkers
|
US20130030359A1
(en)
|
2010-01-22 |
2013-01-31 |
Ascendis Pharma A/S |
Dipeptide-based prodrug linkers for aromatic amine-containing drugs
|
US9062094B2
(en)
|
2010-01-22 |
2015-06-23 |
Ascendis Pharma As |
Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
|
BR112012018585A2
(pt)
|
2010-01-27 |
2017-01-10 |
Univ Indiana Res & Tech Corp |
conjungados e composições de glucagon antagonista-gip agonista para o tratamento de distúrbios metabólicos e de obesidade
|
US20120035320A1
(en)
*
|
2010-04-03 |
2012-02-09 |
University Of Iowa Research Foundation |
Polyacridine nucleic acid delivery peptide complexes
|
CA2797095A1
(fr)
|
2010-05-13 |
2011-11-17 |
Indiana University Research And Technology Corporation |
Peptides de la superfamille des glucagons presentant une activite de recepteur nucleaire d'hormone
|
BR112012028707A2
(pt)
|
2010-05-13 |
2019-09-24 |
Univ Indiana Res & Tech Corp |
composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo.
|
WO2011159895A2
(fr)
|
2010-06-16 |
2011-12-22 |
Indiana University Research And Technology Corporation |
Agonistes de l'insuline à une seule chaîne très actifs au niveau du récepteur à l'insuline
|
JP2013540102A
(ja)
*
|
2010-06-24 |
2013-10-31 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
アミド結合を介して修飾されたグルカゴンスーパーファミリーのペプチドプロドラッグ
|
CA2803164C
(fr)
|
2010-06-24 |
2018-08-21 |
Indiana University Research And Technology Corporation |
Promedicaments insuliniques a base d'amide
|
EP2438930A1
(fr)
*
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Promédicaments comprenant un conjugué de liaison d'exendine
|
JP6086067B2
(ja)
|
2010-12-22 |
2017-03-01 |
インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション |
Gipレセプター活性を示すグルカゴンアナローグ
|
AU2012273365A1
(en)
|
2011-06-22 |
2014-01-16 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
PT2723367T
(pt)
|
2011-06-22 |
2017-08-11 |
Univ Indiana Res & Tech Corp |
Co-agonistas do recetor da glucagina/glp-1
|
BR112013033239A2
(pt)
|
2011-06-22 |
2016-09-06 |
Vyome Biosciences |
pró-farmácos de conjugado baseado em atifungicos e antibacterianos
|
KR20140053991A
(ko)
|
2011-07-18 |
2014-05-08 |
아츠 바이올로직스 에이/에스 |
장기간 작용하는 황체 형성 호르몬 (lh) 화합물
|
CA2843503C
(fr)
|
2011-08-12 |
2020-12-22 |
Ulrich Hersel |
Promedicaments lies a des excipients polymeriques hyperbranches
|
EP3643306A3
(fr)
|
2011-08-12 |
2020-08-26 |
Ascendis Pharma A/S |
Promédicaments liés à un support dotés de liaisons ester carboxylique réversibles
|
AU2012296951B2
(en)
|
2011-08-12 |
2016-09-15 |
Ascendis Pharma A/S |
Protein carrier-linked prodrugs
|
WO2013024047A1
(fr)
|
2011-08-12 |
2013-02-21 |
Ascendis Pharma A/S |
Promédicaments liés à des excipients hydrosolubles de forte charge
|
KR20140103099A
(ko)
|
2011-10-12 |
2014-08-25 |
아센디스 파마 옵탈몰로지 디비젼 에이/에스 |
안구 병태의 예방 및 치료
|
US20140256626A1
(en)
*
|
2011-10-18 |
2014-09-11 |
Prolynx Llc |
Peg conjugates of exenatide
|
RU2014117678A
(ru)
|
2011-11-17 |
2015-12-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
|
CN104114183A
(zh)
|
2011-12-20 |
2014-10-22 |
印第安纳大学研究及科技有限公司 |
用于治疗糖尿病的基于ctp的胰岛素类似物
|
US20150087688A1
(en)
*
|
2012-04-25 |
2015-03-26 |
Ascendis Pharma A/S |
Prodrugs of hydroxyl-comprising drugs
|
EP2846822A2
(fr)
|
2012-05-11 |
2015-03-18 |
Prorec Bio AB |
Méthode de diagnostic et de traitement de troubles associés à la prolactine
|
CN104583232B
(zh)
|
2012-06-21 |
2018-04-13 |
印第安纳大学研究及科技有限公司 |
展现gip受体活性的胰高血糖素类似物
|
CA2883320A1
(fr)
*
|
2012-08-30 |
2014-03-06 |
The Scripps Research Institute |
Molecules petite taille ciblant les sequences r(cgg) repetitives
|
JP6387008B2
(ja)
|
2012-09-26 |
2018-09-05 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
インスリンアナローグダイマー
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
EP2906617B1
(fr)
|
2012-10-11 |
2018-03-14 |
Ascendis Pharma A/S |
Promédicaments à base d'hydrogel
|
MX370543B
(es)
|
2012-10-11 |
2019-12-17 |
Ascendis Pharma Ophthalmology Div A/S |
Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
|
MY186106A
(en)
*
|
2012-10-11 |
2021-06-22 |
Ascendis Pharma As |
Diagnosis, prevention and treatment of diseases of the joint
|
CN104918962B
(zh)
*
|
2012-11-22 |
2017-12-19 |
株式会社糖锁工学研究所 |
糖链加成连接基团、含有糖链加成连接基团部分与生理活性物质部分的化合物或其盐、及其制造方法
|
JP6219308B2
(ja)
|
2012-11-30 |
2017-10-25 |
株式会社糖鎖工学研究所 |
糖鎖付加リンカー、糖鎖付加リンカーと生理活性物質とを含む化合物またはその塩、及びそれらの製造方法
|
MA38276B1
(fr)
|
2012-12-21 |
2018-03-30 |
Sanofi Sa |
Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif.
|
RU2678134C2
(ru)
|
2013-03-14 |
2019-01-23 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Конъюгаты инсулин-инкретин
|
CA2907830C
(fr)
|
2013-04-22 |
2022-03-29 |
Ascendis Pharma A/S |
Promedicaments a liaison hydrogel liberant des medicaments etiquetes
|
CN104178515B
(zh)
*
|
2013-05-21 |
2018-08-31 |
成都先导药物开发有限公司 |
一种化合物的细胞透膜的方法
|
CN104177465B
(zh)
*
|
2013-05-21 |
2017-09-29 |
成都先导药物开发有限公司 |
一种化合物给药前体及药物载体制剂
|
US10040850B2
(en)
|
2013-10-08 |
2018-08-07 |
Ascendis Pharma A/S |
Protecting group comprising a purification tag
|
CA2924661A1
(fr)
*
|
2013-10-08 |
2015-04-16 |
Ascendis Pharma Osteoarthritis Division A/S |
Promedicament il-1ra lie a un hydrogel
|
US20160296600A1
(en)
|
2013-11-11 |
2016-10-13 |
Ascendis Pharma Relaxin Division A/S |
Relaxin Prodrugs
|
US10626156B2
(en)
|
2013-12-06 |
2020-04-21 |
Jie Han |
Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
|
EP3080154B1
(fr)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Agonistes doubles du récepteur glp-1/gip
|
WO2015086730A1
(fr)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Analogues peptidiques de l'exendine 4 non acylés
|
EP3080149A1
(fr)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Agonistes mixtes des récepteurs du glp-1/glucagon
|
WO2015086728A1
(fr)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Analogues peptidiques de l'exendine 4 en tant qu'agonistes mixtes des récepteurs glp-1/gip
|
KR101768446B1
(ko)
|
2014-03-21 |
2017-08-17 |
애니젠 주식회사 |
신규한 엑세나타이드 유사체 및 그의 용도
|
CN104945499B
(zh)
*
|
2014-03-31 |
2019-12-10 |
博瑞生物医药(苏州)股份有限公司 |
结构修饰的glp-1类似物及其制备方法
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
US10328149B2
(en)
|
2014-06-13 |
2019-06-25 |
Tenboron Oy |
Conjugates comprising an anti-EGFR1 antibody
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
AU2015299055C1
(en)
|
2014-08-06 |
2021-05-06 |
Ascendis Pharma A/S |
Prodrugs comprising an aminoalkyl glycine linker
|
WO2016049174A1
(fr)
|
2014-09-24 |
2016-03-31 |
Indiana University Research And Technology Corporation |
Promédicaments insuliniques à base d'amide lipidique
|
ES2822994T3
(es)
|
2014-09-24 |
2021-05-05 |
Univ Indiana Res & Tech Corp |
Conjugados de incretina-insulina
|
JP6946182B2
(ja)
|
2014-10-22 |
2021-10-06 |
エクステンド バイオサイエンシズ インコーポレーテッドExtend Biosciences, Inc |
治療用ビタミンdコンジュゲート
|
US10265413B2
(en)
|
2014-11-05 |
2019-04-23 |
University Of The Sciences In Philadelphia |
High molecular weight biodegradable gelatin-doxorubicin conjugate
|
US20170368189A1
(en)
*
|
2015-01-09 |
2017-12-28 |
Ascendis Pharma Growth Disorders A/S |
Cnp prodrugs
|
WO2016196124A2
(fr)
|
2015-05-29 |
2016-12-08 |
Ascendis Pharma Inc. |
Promédicaments comprenant un lieur de pyroglutamate
|
AR105319A1
(es)
*
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
BR112018005737A2
(pt)
|
2015-09-23 |
2018-10-09 |
Genentech Inc |
anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, para reduzir ou inibir a angiogênese, para tratar um distúrbio associado à angiogênese, para inibir a permeabilidade vascular, composição, conjugado de anticorpo, proteína de fusão, para identificar uma alteração de resíduos, utilização do anticorpo, utilização do conjugado e utilização da proteína
|
CN106554403B
(zh)
*
|
2015-09-25 |
2021-08-31 |
博瑞生物医药(苏州)股份有限公司 |
艾塞那肽修饰物及其用途
|
TWI660741B
(zh)
|
2015-11-03 |
2019-06-01 |
財團法人工業技術研究院 |
抗體藥物複合物及其製造方法
|
AU2017205693B2
(en)
*
|
2016-01-08 |
2022-03-31 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release CNP agonists with low initial NPR-B activity
|
HRP20221339T1
(hr)
*
|
2016-01-08 |
2023-01-06 |
Ascendis Pharma Growth Disorders A/S |
Cnp predlijekovi s učvršćenjem nosača na cikličkom dijelu peptida
|
IL293979B1
(en)
|
2016-01-08 |
2024-04-01 |
Ascendis Pharma Growth Disorders As |
Controlled-release CNP agonists with increased NEP stability
|
EP3400021A1
(fr)
*
|
2016-01-08 |
2018-11-14 |
Ascendis Pharma Growth Disorders A/S |
Agonistes de cnp à libération contrôlée présentant une faible liaison à npr-c
|
WO2017118707A1
(fr)
|
2016-01-08 |
2017-07-13 |
Ascendis Pharma Growth Disorders A/S |
Agonistes de cnp à libération contrôlée présentant des effets secondaires réduits
|
MX2018008061A
(es)
|
2016-01-08 |
2018-08-23 |
Ascendis Pharma Growth Disorders As |
Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
|
WO2017127528A1
(fr)
*
|
2016-01-19 |
2017-07-27 |
University Of Florida Research Foundation, Inc. |
Agonistes peptoïdes de récepteurs de croissance des fibroblastes
|
US20200276276A1
(en)
*
|
2016-03-01 |
2020-09-03 |
Ascendis Pharma Bone Diseases A/S |
PTH Prodrugs
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
AU2017258242B2
(en)
|
2016-04-29 |
2024-04-04 |
Novozymes A/S |
Treatment of liver, biliary tract and pancreatic disorders
|
WO2018011266A1
(fr)
|
2016-07-13 |
2018-01-18 |
Ascendis Pharma A/S |
Procédé de conjugaison pour promédicaments liés à un support
|
MA46428A
(fr)
|
2016-09-29 |
2019-08-07 |
Ascendis Pharma Bone Diseases As |
Schéma posologique incrémentiel dans des composés de pth à libération contrôlée
|
MX2019003182A
(es)
|
2016-09-29 |
2019-08-05 |
Ascendis Pharma Bone Diseases As |
Compuestos de hormona paratiroidea con bajas relaciones pico - valle.
|
FI3518960T3
(fi)
|
2016-09-29 |
2023-10-04 |
Ascendis Pharma Bone Diseases As |
Annostusohjelma kontrolloidusti vapautuvalle PTH-yhdisteelle
|
CA3037448A1
(fr)
|
2016-09-29 |
2018-04-05 |
Ascendis Pharma Growth Disorders A/S |
Therapie combinee d'agonistes de cnp a liberation controlee
|
AR110299A1
(es)
|
2016-12-02 |
2019-03-13 |
Sanofi Sa |
Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
|
CN110290799A
(zh)
|
2016-12-13 |
2019-09-27 |
防御素治疗学公司 |
用于治疗肺部炎性病症的方法
|
CN110636856A
(zh)
*
|
2016-12-29 |
2019-12-31 |
财团法人生物技术开发中心 |
Klk6-介导的cns-特异性抗体前药激活
|
EP4011396A1
(fr)
|
2017-03-10 |
2022-06-15 |
QuiaPEG Pharmaceuticals AB |
Conjugués libérables
|
CA3055985A1
(fr)
|
2017-03-22 |
2018-09-27 |
Genentech, Inc. |
Compositions de promedicament d'hydrogel d'acide hyaluronique reticule et procedes
|
JOP20190245A1
(ar)
|
2017-04-20 |
2019-10-15 |
Novartis Ag |
أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
|
AU2018351936A1
(en)
*
|
2017-10-06 |
2020-05-14 |
Fundação Calouste Gulbenkian |
Treatment of obesity-related conditions
|
GB2571696B
(en)
|
2017-10-09 |
2020-05-27 |
Compass Pathways Ltd |
Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
|
US20200316172A1
(en)
|
2017-11-10 |
2020-10-08 |
Defensin Therapeutics Aps |
Maturation of mucosal defense and gut/lung function in the preterm infant
|
CA3083315A1
(fr)
|
2017-11-24 |
2019-05-31 |
Defensin Therapeutics Aps |
Prevention et traitement de la reaction du greffon contre l'hote avec des defensines
|
CN109160883B
(zh)
*
|
2017-11-30 |
2021-10-08 |
银隆新能源股份有限公司 |
一种蒽醌盐正极材料及其合成方法
|
AU2018378348A1
(en)
|
2017-12-05 |
2020-06-18 |
Sunovion Pharmaceuticals Inc. |
Crystal forms and production methods thereof
|
WO2019113079A1
(fr)
|
2017-12-05 |
2019-06-13 |
Sunovion Pharmaceuticals Inc. |
Mélanges non racémiques et leurs utilisations
|
AU2018378812A1
(en)
|
2017-12-06 |
2020-07-09 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle atrophy and myotonic dystrophy
|
CA3093083A1
(fr)
|
2018-03-28 |
2019-10-03 |
Ascendis Pharma A/S |
Conjugues
|
EP3773680A1
(fr)
|
2018-03-28 |
2021-02-17 |
Ascendis Pharma Oncology Division A/S |
Conjugués d'il-2
|
US10799138B2
(en)
|
2018-04-05 |
2020-10-13 |
University Of Maryland, Baltimore |
Method of administering sotalol IV/switch
|
US11028123B2
(en)
|
2018-04-10 |
2021-06-08 |
Sanofi-Aventis Deutschland Gmbh |
Capping of unprotected amino groups during peptide synthesis
|
JP7434169B2
(ja)
|
2018-04-10 |
2024-02-20 |
サノフィ-アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
固相からの固相結合ペプチドの切断方法
|
EP3793587A1
(fr)
|
2018-05-18 |
2021-03-24 |
Ascendis Pharma Bone Diseases A/S |
Dose initiale de conjugués de la pth
|
TW202015735A
(zh)
|
2018-05-30 |
2020-05-01 |
法商賽諾菲公司 |
包含glp-1/升糖素/gip三重受體促效劑、連接子及透明質酸之接合物
|
US11344518B2
(en)
|
2018-08-14 |
2022-05-31 |
AltaThera Pharmaceuticals LLC |
Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
|
US10512620B1
(en)
|
2018-08-14 |
2019-12-24 |
AltaThera Pharmaceuticals, LLC |
Method of initiating and escalating sotalol hydrochloride dosing
|
US11610660B1
(en)
|
2021-08-20 |
2023-03-21 |
AltaThera Pharmaceuticals LLC |
Antiarrhythmic drug dosing methods, medical devices, and systems
|
US11696902B2
(en)
|
2018-08-14 |
2023-07-11 |
AltaThera Pharmaceuticals, LLC |
Method of initiating and escalating sotalol hydrochloride dosing
|
JP2021535920A
(ja)
|
2018-09-12 |
2021-12-23 |
キアペグ ファーマシューティカルズ アクチエボラグ |
放出可能なglp−1コンジュゲート
|
WO2020064847A1
(fr)
|
2018-09-26 |
2020-04-02 |
Ascendis Pharma A/S |
Hydrogels dégradables d'acide hyaluronique
|
US20210330807A1
(en)
|
2018-09-26 |
2021-10-28 |
Ascendis Pharma A/S |
Novel hydrogel conjugates
|
US20210330798A1
(en)
|
2018-09-26 |
2021-10-28 |
Ascendis Pharma A/S |
Treatment of infections
|
TW202027794A
(zh)
|
2018-10-03 |
2020-08-01 |
瑞士商諾華公司 |
血管生成素樣3多肽之持續遞送
|
CN109125707B
(zh)
*
|
2018-10-19 |
2022-01-04 |
艾伟伦 |
GnRH类似物缓释组合物及其制备方法
|
JP2022516314A
(ja)
|
2019-01-04 |
2022-02-25 |
アセンディス ファーマ オンコロジー ディヴィジョン エー/エス |
自然免疫アゴニストのための持続性局所性薬物レベル
|
EP3906018A1
(fr)
|
2019-01-04 |
2021-11-10 |
Ascendis Pharma Oncology Division A/S |
Induction d'une inflammation locale soutenue
|
CA3125533A1
(fr)
|
2019-01-04 |
2020-07-09 |
Ascendis Pharma Oncology Division A/S |
Conjugues d'agonistes du recepteur de reconnaissance de motif
|
CA3125541A1
(fr)
|
2019-01-04 |
2020-07-09 |
Ascendis Pharma Oncology Division A/S |
Minimisation de l'inflammation systemique
|
US20220118053A1
(en)
|
2019-02-11 |
2022-04-21 |
Ascendis Pharma Growth Disorders A/S |
Dry Pharmaceutical Formulations of CNP Conjugates
|
US20220088149A1
(en)
|
2019-02-11 |
2022-03-24 |
Ascendis Pharma Bone Diseases A/S |
Liquid Pharmaceutical Formulations of PTH Conjugates
|
JP2022529781A
(ja)
|
2019-04-17 |
2022-06-24 |
コンパス パスファインダー リミテッド |
サイロシビンによるうつ病及び他の様々な障害の治療
|
CA3142355A1
(fr)
|
2019-06-04 |
2020-12-10 |
Sunovion Pharmaceuticals Inc. |
Formulations a liberation modifiee et utilisations associees
|
WO2020254612A1
(fr)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Composés inhibiteurs de tyrosine kinases à libération contrôlée présentant des propriétés pharmacodynamiques localisées
|
CA3143442A1
(fr)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma A/S |
Conjugues de composes heteroaromatiques contenant de l'azote
|
WO2020254617A1
(fr)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Composés anti-ctla4 présentant des propriétés pharmacocinétiques localisées
|
TW202114660A
(zh)
|
2019-06-21 |
2021-04-16 |
丹麥商阿仙帝斯製藥公司 |
酪胺酸激酶抑制劑結合物
|
WO2020254613A1
(fr)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Composés inhibiteurs de tyrosine kinase à libération contrôlée présentant des propriétés pharmacocinétiques localisées
|
EP3986479A1
(fr)
|
2019-06-21 |
2022-04-27 |
Ascendis Pharma Oncology Division A/S |
Conjugués anti-ctla4
|
KR20220024690A
(ko)
|
2019-06-21 |
2022-03-03 |
아센디스 파마 에이에스 |
π 전자쌍 공여 헤테로방향족 질소 포함 화합물의 컨쥬게이트
|
WO2020254607A1
(fr)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Composés anti-ctla4 à propriétés pd localisées
|
MX2022007916A
(es)
|
2020-01-03 |
2022-07-21 |
Ascendis Pharma As |
Conjugados que experimentan rearreglos intramoleculares.
|
KR20220128390A
(ko)
|
2020-01-13 |
2022-09-20 |
아센디스 파마 본 디지즈 에이/에스 |
부갑상선기능저하증 치료
|
IL296387B1
(en)
|
2020-03-19 |
2024-04-01 |
Avidity Biosciences Inc |
Preparations and methods for the treatment of facial, back and arm muscle atrophy
|
EP4146281A1
(fr)
|
2020-05-04 |
2023-03-15 |
Ascendis Pharma A/S |
Irradiation d'hydrogel
|
TW202210502A
(zh)
|
2020-06-03 |
2022-03-16 |
丹麥商阿森迪斯腫瘤製藥有限公司 |
新穎il-2序列及其用途
|
AU2021319863A1
(en)
|
2020-08-05 |
2023-02-16 |
Ascendis Pharma A/S |
Conjugates comprising reversible linkers and uses thereof
|
AU2021335032A1
(en)
|
2020-08-28 |
2023-03-09 |
Ascendis Pharma Oncology Division A/S |
Glycosylated IL-2 proteins and uses thereof
|
US20230322743A1
(en)
*
|
2020-09-11 |
2023-10-12 |
Compass Pathfinder Limited |
Novel safrylamine derivatives having prodrug properties
|
EP4217004A1
(fr)
|
2020-09-28 |
2023-08-02 |
Ascendis Pharma Bone Diseases A/S |
Amélioration du bien-être physique et mental de patients atteints d'hypoparathyroïdisme
|
KR20230164709A
(ko)
|
2021-04-01 |
2023-12-04 |
아센디스 파마 에이에스 |
염증 유발 질환을 치료하기 위한 지속형 성장 호르몬의 용도
|
WO2023034510A1
(fr)
|
2021-09-01 |
2023-03-09 |
ATAI Life Sciences AG |
Synthèse de mdma ou de ses isomères optiquement actifs (r)- ou (s)-mdma
|
CN113842379B
(zh)
*
|
2021-09-12 |
2024-04-23 |
东北农业大学 |
倍他洛尔作为ndm-1抑制剂或抗生素保护剂的新用途
|
KR20240055874A
(ko)
|
2021-09-16 |
2024-04-29 |
어비디티 바이오사이언시스 인크. |
안면견갑상완 근이영양증을 치료하는 조성물 및 방법
|
AU2022350937A1
(en)
|
2021-09-22 |
2024-03-21 |
Ascendis Pharma Bone Diseases A/S |
Long-acting pth compound treatments
|
WO2023056102A1
(fr)
|
2021-10-01 |
2023-04-06 |
ATAI Life Sciences AG |
Nouveaux promédicaments de mdma, mda et leurs dérivés
|
WO2023110727A2
(fr)
|
2021-12-13 |
2023-06-22 |
Ascendis Pharma Oncology Division A/S |
Nouveaux traitements du cancer avec des agonistes de tlr7/8
|
AU2022413318A1
(en)
|
2021-12-13 |
2024-05-16 |
Ascendis Pharma Growth Disorders A/S |
Effective doses of cnp conjugates
|
US11912680B2
(en)
|
2021-12-28 |
2024-02-27 |
Empathbio, Inc. |
Nitric oxide releasing prodrugs of MDA and MDMA
|
WO2023227505A1
(fr)
|
2022-05-23 |
2023-11-30 |
Ascendis Pharma Growth Disorders A/S |
Formulations pharmaceutiques liquides de composés cnp
|
WO2024094673A1
(fr)
|
2022-11-02 |
2024-05-10 |
Ascendis Pharma Bone Diseases A/S |
Régime de traitement à base de pth comprenant deux composés pth
|
WO2024104922A1
(fr)
|
2022-11-14 |
2024-05-23 |
Ascendis Pharma Growth Disorders A/S |
Procédé d'amélioration de la fonction musculaire squelettique
|